Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Construction in Progress: 2021-2023

Historic Construction in Progress for Arrowhead Pharmaceuticals (ARWR) over the last 3 years, with Sep 2023 value amounting to $166.7 million.

  • Arrowhead Pharmaceuticals' Construction in Progress rose 195.63% to $166.7 million in Q3 2023 from the same period last year, while for Sep 2023 it was $166.7 million, marking a year-over-year increase of 195.63%. This contributed to the annual value of $166.7 million for FY2023, which is 195.63% up from last year.
  • As of FY2023, Arrowhead Pharmaceuticals' Construction in Progress stood at $166.7 million, which was up 195.63% from $56.4 million recorded in FY2022.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Construction in Progress peaked at $166.7 million during FY2023, and registered a low of $345,000 during FY2021.
  • Its 3-year average for Construction in Progress is $74.5 million, with a median of $56.4 million in 2022.
  • Data for Arrowhead Pharmaceuticals' Construction in Progress shows a peak YoY spiked of 16,240.00% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows Arrowhead Pharmaceuticals' Construction in Progress stood at $345,000 in 2021, then surged by 16,240.00% to $56.4 million in 2022, then skyrocketed by 195.63% to $166.7 million in 2023.